Leriglitazone

Leriglitazone (MIN-102; Hydroxypioglitazone) is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases^[1][2][3][4]. In Vitro:Leriglitazone (100 nM; 45 days) increases PKAN astrocyte activity and respiratory activity, and reduces iron accumulation^[1].
Leriglitazone (50-500 nM; 5 days) increases Frataxin levels, promots cell survival and improves neuronal degeneration and mitochondrial function in Frataxin-deficient DRG neurons^[2].
Leriglitazone (0.5-2 μM; 7 days) prevents lipid droplet accumulation in frataxin-deficient cardiomyocytes^[2].
Leriglitazone (100-500 nM; 48 h) regulates the expression of PPARγ signaling pathway related genes, increases mitochondrial function and reduces oxidative damage in Rett fibroblasts^[3]. In Vivo:Leriglitazone (50 mg/kg; Feed administration; 8 months) improves motor impairment in a Friedreich ataxia mouse model^[2].
Leriglitazone (75 mg/kg; Feed administration; 7 months) has an improved effect in Rett mouse model^[3].